vimarsana.com

University Of Copenhagen Novo Nordisk Foundation Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Still Hungry for New Obesity Meds, Novo Nordisk Makes Another M&A Deal

Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark’s science comes University of Copenhagen research on a novel fat cell target.

vimarsana © 2020. All Rights Reserved.